RU99104772A - GNRH CHIMERS (GIVG) -LEYKOTOKSIN - Google Patents
GNRH CHIMERS (GIVG) -LEYKOTOKSINInfo
- Publication number
- RU99104772A RU99104772A RU99104772/13A RU99104772A RU99104772A RU 99104772 A RU99104772 A RU 99104772A RU 99104772/13 A RU99104772/13 A RU 99104772/13A RU 99104772 A RU99104772 A RU 99104772A RU 99104772 A RU99104772 A RU 99104772A
- Authority
- RU
- Russia
- Prior art keywords
- gnrh
- polypeptide
- amino acid
- terminus
- chimeric protein
- Prior art date
Links
- 102100000899 GNRH1 Human genes 0.000 title 1
- 101710012696 GNRH1 Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 23
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 17
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims 17
- 101700070063 lktA Proteins 0.000 claims 14
- 101700063372 ltxA Proteins 0.000 claims 14
- XEBKSQSGNGRGDW-YFHOEESVSA-N 9,10-DiHOME Chemical compound CCCCC\C=C/CC(O)C(O)CCCCCCCC(O)=O XEBKSQSGNGRGDW-YFHOEESVSA-N 0.000 claims 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 11
- 108020001507 fusion proteins Proteins 0.000 claims 11
- 102000037240 fusion proteins Human genes 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000000875 corresponding Effects 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960005486 vaccines Drugs 0.000 claims 3
- 230000000890 antigenic Effects 0.000 claims 2
- 230000001472 cytotoxic Effects 0.000 claims 2
- 208000000409 Breast Neoplasms Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Claims (24)
[GnRH-X-GnRH]n,
где GnRH представляет собой полипептид GnRH;
X выбирается из группы, содержащей пептидную связь, группу аминокислотного спейсера и полипептид лейкотоксина;
n означает целое число, большее или равное 1.2. Chimeric protein according to claim 1, characterized in that the first and second multimers of GnRH are different and are part of the molecules corresponding to the general formula
[GnRH-X-GnRH] n,
where GnRH is a GnRH polypeptide;
X is selected from the group comprising a peptide bond, an amino acid spacer group and a leukotoxin polypeptide;
n means an integer greater than or equal to 1.
[GnRH-X-GnRH]n,
где GnRH представляет собой полипептид GnRH;
X выбирается из группы, содержащей пептидную связь, аминокислотную спейсерную группу и полипептид лейкотоксина;
n означает целое число, большее или равное 1.3. The chimeric protein according to claim 1, characterized in that the first and second GnRH multimers are the same and are part of the molecules corresponding to the general formula
[GnRH-X-GnRH] n,
where GnRH is a GnRH polypeptide;
X is selected from the group comprising a peptide bond, an amino acid spacer group and a leukotoxin polypeptide;
n means an integer greater than or equal to 1.
[GnRH-X-GnRH]n,
в которой GnRH представляет собой полипептид GnRH;
X - выбирается из группы, содержащей пептидную связь, группу аминокислотного спейсера и полипептид лейкотоксина;
n означает целое число, большее или равное 1.13. DNA construction according to item 12, characterized in that the first and second GnRH multimers are different and are part of the molecules corresponding to the general formula
[GnRH-X-GnRH] n,
in which GnRH is a GnRH polypeptide;
X is selected from the group comprising a peptide bond, an amino acid spacer group and a leukotoxin polypeptide;
n means an integer greater than or equal to 1.
[GnRH-X-GnRH]n,
в которой GnRH представляет собой полипептид GnRH;
X - выбирается из группы, содержащей пептидную связь, аминокислотную спейсерную группу и полипептид лейкотоксина;
n означает целое число, большее или равное 1.14. The DNA construct according to claim 12, characterized in that the first and second GnRH multimers are the same and are part of the molecules corresponding to the general formula
[GnRH-X-GnRH] n,
in which GnRH is a GnRH polypeptide;
X is selected from the group comprising a peptide bond, an amino acid spacer group and a leukotoxin polypeptide;
n means an integer greater than or equal to 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/694,865 | 1996-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU99104772A true RU99104772A (en) | 2001-02-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pennica et al. | Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin | |
Dingwall et al. | Nucleoplasmin cDNA sequence reveals polyglutamic acid tracts and a cluster of sequences homologous to putative nuclear localization signals. | |
Bringman et al. | Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes | |
KR960704038A (en) | Cytokines That Bind the Cell Surface Receptor Hek | |
US7252967B2 (en) | Nucleic acids encoding cytokine-like proteins that promote cell proliferation | |
RU94045919A (en) | Antibodies, cells, polypeptide, dna, vectors, method of polypeptide preparing, method of antibody preparing, pharmaceutical composition | |
RU2006105498A (en) | POLYEPEPTIDES FOR THE INDUCTION OF A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS | |
CA2641565A1 (en) | Nel-related proteins type 1 and 2, and polynucleotides encoding them | |
KR970701776A (en) | Transforming growth factor alpha H1 | |
CA2209360A1 (en) | Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen | |
PL336295A1 (en) | Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna | |
RU2002124123A (en) | MODIFIED FACTOR VIII | |
EP0605653A1 (en) | A new form of liposaccharide binding protein (lbp) | |
JP2007502101A5 (en) | ||
JP2004531242A5 (en) | ||
AU3406595A (en) | Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus | |
ES2235156T3 (en) | EXPRESSION AND PURIFICATION OF CLONE HUMAN ALFA-PHETOPROTEIN. | |
ATE338113T1 (en) | TRANSFERRIN RECEPTOR GENES OF HAEMOPHILUS | |
CA2020700A1 (en) | Compositions for the inhibition of protein hormone formation and uses thereof | |
EA016818B1 (en) | Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1 | |
JPH05506247A (en) | Antagonist of human gamma interferon | |
Negro et al. | Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli | |
ES2244993T3 (en) | RECOMBINANT METHOD FOR THE PREPARATION OF A COMPLETE OLD MALARIA GP190 / MSP1. | |
KR940021579A (en) | Bone-related transcriptional regulator proteins and methods for their preparation | |
ATE357526T1 (en) | MODIFIED HCV PEPTIDE VACCINES |